Advertisement
CRSP vs EDIT
Which Stock Would AI Choose? CRISPR Therapeutics (CRSP) vs. Editas Medicine (EDIT) Stock Comparison
Key Takeaways
- Different stages of maturity: CRSP has an FDA-approved therapy (Casgevy) and growing commercial revenue, while EDIT is a pre-commercial, clinical-stage company with no approved products.
- Contrasting momentum: EDIT has outperformed over the trailing year on a percentage basis, driven by pipeline catalysts, while CRSP has moved more modestly despite its commercial asset.
- Scale and balance sheet: CRSP holds a substantially larger cash position and market capitalization, giving it a longer runway than EDIT's leaner balance sheet.
- Pipeline focus differs: CRSP is advancing cardiovascular, oncology, and autoimmune programs, while EDIT is concentrated on its lead in vivo candidate, EDIT-401, targeting high LDL cholesterol.
- Risk profiles diverge: EDIT carries higher binary clinical risk but also a larger implied upside, whereas CRSP offers a comparatively more established, diversified story.
- For more detail on each company, explore CRSP Major News and CRSP Today's Price Move, or EDIT Major News and EDIT Today's Price Move.
- To see how automated systems are positioning across these and thousands of other tickers, explore Trending AI Robots.
Introduction
Both CRSP (CRISPR Therapeutics AG) and EDIT (Editas Medicine, Inc.) are pioneers in gene editing, using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology to develop medicines. Yet they sit at very different points on the commercialization curve. CRSP has already brought a therapy to market and is scaling a diversified pipeline, while EDIT is still proving its lead candidate in early human studies. This stock comparison is most relevant for investors weighing a more established, cash-rich gene-editing company against a smaller, higher-risk, higher-upside clinical-stage name.
CRSP Overview and Recent Performance
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using its CRISPR/Cas9 platform. Its flagship therapy, Casgevy, developed with Vertex Pharmaceuticals, is approved to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TBT), two inherited blood disorders. In recent market activity, CRSP has traded in a comparatively narrow range, supported by steadily improving Casgevy uptake and a series of analyst price-target increases. Recent weeks brought a notable leadership transition, with the company appointing Andrew J. Silver as chief financial officer, a move viewed largely as continuity. Near-term sentiment has also been shaped by anticipation of clinical data, including Phase 1b results for CTX310, a cardiovascular candidate, presented at a major medical meeting. Despite this progress, the company remains unprofitable, and its revenue is still modest relative to its spending, keeping performance tied to pipeline milestones.
EDIT Overview and Recent Performance
Editas Medicine is a clinical-stage gene-editing company focused on in vivo (inside the body) therapies. Unlike CRSP, EDIT currently has no approved products. Its lead candidate, EDIT-401, is designed to edit the LDLR gene to durably lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH), an inherited condition that elevates heart-disease risk. In recent weeks, EDIT received clearance to begin the Phase 1/2 "Strive" clinical trial in Australia, a milestone that triggered analyst upgrades and a share-price jump. Preclinical data showing roughly 90% or greater reductions in LDL cholesterol in non-human primates has underpinned investor optimism. The company's leaner balance sheet and concentrated pipeline mean its near-term trajectory is closely tied to early safety and efficacy readouts, with initial data expected in the first quarter of 2027.
Trending AI Robots
Tickeron operates a large suite of AI trading bots covering thousands of individual tickers, each running distinct strategies, timeframes, and statistical profiles. Because market conditions shift constantly, only a subset of these bots are well-matched to the current environment at any given moment. That is the purpose of the Trending AI Robots page: it curates a focused list of the highest-performing, most relevant bots so traders can review their strategies and performance statistics without sifting through the full catalog. The bots differ widely in trading style, holding period, and the set of tickers they trade, offering options for a range of risk tolerances and objectives. If you are interested in how automated, data-driven systems are approaching names like CRSP and EDIT, the Trending AI Robots page is a useful starting point.
Head-to-Head Comparison
The most fundamental contrast between these two companies is commercial maturity. CRSP generates collaboration revenue tied to Casgevy and operates a broader pipeline spanning cardiometabolic, oncology, and autoimmune programs, supported by a cash position of roughly $1.9 billion. EDIT, by comparison, is essentially a single-asset story centered on EDIT-401, with a much smaller cash reserve and a market capitalization in the hundreds of millions rather than billions. This shapes their risk-return profiles: EDIT offers greater relative upside on clinical success but higher binary risk, whereas CRSP presents a more diversified, lower-volatility exposure to the gene-editing theme. Sector exposure is similar, but growth drivers diverge, with CRSP leaning on commercial execution and multiple pipeline readouts, and EDIT focused on proof-of-concept data for a single cholesterol-lowering therapy.
Tickeron AI Verdict
Based on observable factors such as trend consistency, financial stability, and catalyst breadth, Tickeron's AI would likely favor CRSP as the more resilient positioning. Its larger cash runway, established commercial asset, and more diversified pipeline tend to produce steadier trends and lower downside volatility. That said, EDIT has demonstrated stronger recent momentum and a potentially higher upside trajectory if its lead candidate delivers positive early data. In probabilistic terms, CRSP appears better suited to risk-averse positioning, while EDIT may appeal to traders seeking higher-beta (more volatile) exposure to near-term catalysts. These assessments reflect relative positioning rather than a definitive outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and EDIT is a StrongBuy.
CRSP's Stochastic Oscillator stays in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +5.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 38 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.498). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CRSP | EDIT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 99 | |
PRICE GROWTH RATING 1..100 | 72 | 71 | |
P/E GROWTH RATING 1..100 | 54 | 30 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (24) in the Biotechnology industry is in the same range as EDIT (53). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.
CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as EDIT (99). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (71) in the Biotechnology industry is in the same range as CRSP (72). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.
EDIT's P/E Growth Rating (30) in the Biotechnology industry is in the same range as CRSP (54). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.
| CRSP | EDIT | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 89% |
| Advances ODDS (%) | 15 days ago 82% | 4 days ago 80% |
| Declines ODDS (%) | 3 days ago 81% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).
- CRSP’s FA Score: 1 green, 4 red.
- EDIT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 3 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).
- CRSP’s TA Score: 3 bullish, 5 bearish.
- EDIT’s TA Score: 3 bullish, 6 bearish.
Price Growth
CRSP (@Biotechnology) experienced а -11.64% price change this week, while EDIT (@Biotechnology) price change was -12.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
CRSP is expected to report earnings on Feb 16, 2027.
EDIT is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -4.99% | ||
| BEAM - EDIT | 67% Closely correlated | +2.62% | ||
| CRSP - EDIT | 63% Loosely correlated | +1.33% | ||
| SLDB - EDIT | 62% Loosely correlated | +6.00% | ||
| PRME - EDIT | 61% Loosely correlated | +10.26% | ||
| VYGR - EDIT | 61% Loosely correlated | -3.56% | ||
More | ||||